Compare Oscar Health Inc (OSCR) vs Remitly Global Inc (RELY) Price & Performance

Oscar Health (OSCR) trades at $29.60, up 1.72% with mixed technical signals showing neutral overall momentum. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative margins. Revenue growth from $11.7B in 2025 to projected $13.3B in 2026 indicates expansion, while cash flow trends show operational improvement. Analyst consensus is divided with 27% buy ratings against a $24.67 price target below current levels.

The stock presents growth potential through revenue expansion and cash flow generation, but profitability concerns and negative ROE pose significant risks. Current valuation at 0.61 P/S suggests reasonable pricing for growth, though execution on margin improvement remains critical for sustained upside.

RELY trades at $23.83, down 1.24% on the day, with a bullish technical signal from moving averages. The company has demonstrated a strong turnaround, achieving profitability in 2025 with net income of $67.93 million after years of losses. Revenue growth is robust, reaching $1.64 billion in 2025, with positive cash flow from operations of $325.08 million. Recent news highlights expansion, including a new license in the UAE and raised full-year guidance for 2026.

The outlook is positive, driven by accelerating revenue growth, market share gains in the remittance sector, and a clear path to sustained profitability. Key risks include intense competition from established payment giants and execution challenges in international expansion. With a consensus analyst price target of $28.50 implying significant upside, the stock presents a growth opportunity, though investors should be mindful of its premium valuation multiples.